Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Benefit-Risk Assessments For Me-Too Drugs Encouraged By FDA

Executive Summary

Sponsors should complete agency’s structured benefit-risk framework to help reviewers better understand the reason the product is needed in the marketplace.

You may also be interested in...



Group Submits Duchenne Muscular Dystrophy Guidance, Hoping To Direct FDA Policy

Parent Project Muscular Dystrophy’s proposed guidance gives detail on biomarkers and clinical trial designs for the beleaguered field, but most importantly addresses benefit-risk assessment – which is FDA’s underlying ambition for the patient-focused drug development initiative.

Fibromyalgia Patient Meeting Shines Light On Lesser Known Symptoms

While pain and fatigue are well-recognized symptoms of fibromyalgia, patients testifying at the PDUFA V disease area meeting gave FDA drug review staff insight into other health effects, such as visual disturbances.

More Me-Too Drugs Please, FDA’s Jenkins Asks Industry

FDA’s top new drug official called out industry’s innovation model, noting that major primary care markets are being left underserved as sponsors focus on precision medicine and rare diseases.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS056049

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel